Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) major shareholder Ra Capital Management, L.P. sold 128,770 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $0.39, for a total transaction of $50,220.30. Following the sale, the insider directly owned 341,353 shares in the company, valued at approximately $133,127.67. The trade was a 27.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Tuesday, June 16th, Ra Capital Management, L.P. sold 149,625 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total transaction of $55,361.25.
- On Friday, June 12th, Ra Capital Management, L.P. sold 170,441 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.40, for a total transaction of $68,176.40.
- On Thursday, June 11th, Ra Capital Management, L.P. sold 262,503 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.38, for a total transaction of $99,751.14.
- On Wednesday, June 10th, Ra Capital Management, L.P. sold 45,923 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total transaction of $16,991.51.
- On Tuesday, June 9th, Ra Capital Management, L.P. sold 369,800 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total transaction of $136,826.00.
- On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $64,736.64.
- On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.67, for a total transaction of $58,618.30.
- On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.71, for a total transaction of $267,333.46.
Werewolf Therapeutics Trading Down 7.4%
Shares of Werewolf Therapeutics stock opened at $0.36 on Wednesday. The firm has a market capitalization of $17.50 million, a PE ratio of -0.29 and a beta of 0.29. Werewolf Therapeutics, Inc. has a twelve month low of $0.36 and a twelve month high of $2.38. The firm's 50-day moving average price is $0.63 and its 200 day moving average price is $0.70.
Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.32) by $0.04. On average, sell-side analysts predict that Werewolf Therapeutics, Inc. will post -1.08 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. Qube Research & Technologies Ltd purchased a new position in Werewolf Therapeutics in the 2nd quarter worth approximately $48,000. Regal Investment Advisors LLC lifted its stake in Werewolf Therapeutics by 93.3% in the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company's stock worth $33,000 after purchasing an additional 25,389 shares in the last quarter. Vontobel Holding Ltd. lifted its stake in Werewolf Therapeutics by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company's stock worth $38,000 after purchasing an additional 24,003 shares in the last quarter. AQR Capital Management LLC purchased a new position in Werewolf Therapeutics in the 1st quarter worth approximately $79,000. Finally, Susquehanna International Group LLP lifted its stake in Werewolf Therapeutics by 16.9% in the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company's stock worth $183,000 after purchasing an additional 13,439 shares in the last quarter. 64.84% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of brokerages recently weighed in on HOWL. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Wall Street Zen lowered shares of Werewolf Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, May 9th. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Werewolf Therapeutics has an average rating of "Hold" and a consensus price target of $3.75.
Get Our Latest Stock Report on Werewolf Therapeutics
About Werewolf Therapeutics
(
Get Free Report)
Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company's proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.
Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
